Evidence map›Paper›PMID 35326770›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Polymyxin Induces Significant Transcriptomic Perturbations of Cellular Signalling Networks in Human Lung Epithelial Cells.

Mengyao Li, Mohammad A K Azad, Maizbha U Ahmed, Yan Zhu, Jiangning Song, Fanfan Zhou, Hak-Kim Chan, Tony Velkov, Qi Tony Zhou, Jian Li

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Mengyao LiBiomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Melbourne, VIC 3800, Australia.
Mohammad A K AzadBiomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Melbourne, VIC 3800, Australia.
Maizbha U AhmedDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.ORCID 0000-0002-5221-2502
Yan ZhuBiomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0001-7342-3782
Jiangning SongBiomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0001-8031-9086
Fanfan ZhouSydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
Hak-Kim ChanAdvanced Drug Delivery Group, Sydney Pharmacy School, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-7054-3137
Tony VelkovDepartment of Pharmacology and Therapeutic Sciences, University of Melbourne, Melbourne, VIC 3010, Australia.ORCID 0000-0002-0017-7952
Qi Tony ZhouDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
Jian LiBiomedicine Discovery Institute, Infection & Immunity Program and Department of Microbiology, Monash University, Melbourne, VIC 3800, Australia.
Australian Regenerative Medicine Institute · AUPurdue University West Lafayette · USThe University of Sydney · AUThe University of Melbourne · AU

Funding

Advancing innovative therapies against pandrug-resistant Gram-negative superbugsR01AI146160 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2019 to 2023
$3.2M
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems ApproachR01AI132681 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2017 to 2020
$2.4M
National Health and Medical Research Council APP1104581NIAID NIH HHS R01 AI132681NIAID NIH HHS R01 AI146160NIH HHS R01 AI132681NIH HHS R01 AI146160
6 · The paper itself

Abstract

Inhaled polymyxins are increasingly used to treat pulmonary infections caused by multidrug-resistant Gram-negative pathogens. We have previously shown that apoptotic pathways, autophagy and oxidative stress are involved in polymyxin-induced toxicity in human lung epithelial cells. In the present study, we employed human lung epithelial cells A549 treated with polymyxin B as a model to elucidate the complex interplay of multiple signalling networks underpinning cellular responses to polymyxin toxicity. Polymyxin B induced toxicity (1.0 mM, 24 h) in A549 cells was assessed by flow cytometry and transcriptomics was performed using microarray. Polymyxin B induced cell death was 19.0 ± 4.2% at 24 h. Differentially expressed genes (DEGs) between the control and polymyxin B treated cells were identified with Student’s t-test. Pathway analysis was conducted with KEGG and Reactome and key hub genes related to polymyxin B induced toxicity were examined using the STRING database. In total we identified 899 DEGs (FDR < 0.01), KEGG and Reactome pathway analyses revealed significantly up-regulated genes related to cell cycle, DNA repair and DNA replication. NF-κB and nucleotide-binding oligomerization domain-like receptor (NOD) signalling pathways were identified as markedly down-regulated genes. Network analysis revealed the top 5 hub genes (i.e., degree) affected by polymyxin B treatment were PLK1(48), CDK20 (46), CCNA2 (42), BUB1 (40) and BUB1B (37). Overall, perturbations of cell cycle, DNA damage and pro-inflammatory NF-κB and NOD-like receptor signalling pathways play key roles in polymyxin-induced toxicity in human lung epithelial cells. Noting that NOD-like receptor signalling represents a group of key sensors for microorganisms and damage in the lung, understanding the mechanism of polymyxin-induced pulmonary toxicity will facilitate the optimisation of polymyxin inhalation therapy in patients.

Indexed as

lung epithelial cellspolymyxinpulmonary toxicitytranscriptomics

Identifiers

PMID35326770
PMCPMC8944768
OpenAlexW4213413867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.